Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 797 across all filing types
Latest filing 2014-11-04 Earnings Release
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming Confirms Receipt of US$20 Million Milestone Payment from Salix Pharmaceuticals
Earnings Release Classification · 95% confidence The document is a press release dated November 4, 2014, announcing the receipt of a US$20 million milestone payment from Salix Pharmaceuticals related to the Ruconest® commercialization agreement. It discusses financial strengthening, future revenue streams, and provides company background. This type of announcement, focusing on a specific financial event (milestone payment) and its immediate impact, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full quarterly report (IR) or an annual report (10-K), and it is a direct announcement of financial results/events rather than a presentation (IP) or a transcript (CT), the most appropriate classification is Earnings Release (ER), as it details key financial highlights for the period/event. Given the short length and press release format, it is not a comprehensive report. FY 2014
2014-11-04 English
PHARMING AND SALIX ANNOUNCE THE LAUNCH OF RUCONEST® IN THE U.S. FOR THE TREATMENT OF ACUTE ANGIOEDEMA ATTACKS IN PATIENTS WITH HEREDITARY ANGIOEDEMA (HAE)
Regulatory Filings Classification · 95% confidence The document is a press release dated November 3, 2014, announcing the launch of the drug RUCONEST® in the U.S. by Pharming and Salix. It details the drug's indication, safety information, and commercialization strategy. This type of announcement, which communicates significant business or product news outside of mandatory periodic financial reports (like 10-K or 10-Q) or specific corporate actions (like dividends or management changes), typically falls under general regulatory announcements or news releases. Since it is not a full financial report (10-K, IR), a specific financial event (CAP, DIV), or a management change (MANG), the most appropriate general category for a significant, non-standard corporate announcement is Regulatory Filings (RNS), which serves as a broad category for such disclosures, especially when the content is primarily commercial/product news.
2014-11-03 English
PHARMING REPORTS ON FINANCIAL RESULTS FOR THE FIRST NINE MONTHS OF 2014
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the nine-month period ended September 30, 2014. It includes detailed financial highlights, operational updates, management commentary, and full condensed consolidated interim financial statements (Statement of Financial Position, Statement of Income, etc.). It is not merely an announcement or a short summary, but the actual interim report containing substantive financial data, thus fitting the definition of an Interim/Quarterly Report (IR). 9M 2014
2014-10-30 English
Interim / Quarterly Report 2014
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the nine-month period ended September 30, 2014. It includes detailed financial highlights, operational updates, management commentary, and full condensed consolidated interim financial statements (Statement of Financial Position, Statement of Income, etc.). It is not merely an announcement or a short summary, but the actual interim report containing substantive financial data, thus fitting the definition of an Interim/Quarterly Report (IR). 9M 2014
2014-10-30 English
PHARMING AND SWEDISH ORPHAN BIOVITRUM AMEND AND EXTEND RUCONEST DISTRIBUTION AGREEMENT
M&A Activity Classification · 99% confidence The document is a press release dated October 13, 2014, announcing an amendment and extension of a distribution agreement between Pharming and Sobi regarding the drug Ruconest®. It details changes in commercialization territories and operational handover. This type of announcement, which concerns business operations, partnerships, and strategic changes rather than routine financial reporting (like 10-K, ER, IR) or specific corporate governance events (like AGM, DEF 14A), fits best under the general category for significant corporate news that doesn't have a more specific code. Since it is not a formal regulatory filing like a 10-K or a specific financial report, and it is not about management changes (MANG) or director dealings (DIRS), the most appropriate classification is the general Regulatory Filings/Announcements category (RNS), as it is a public announcement of a material business event.
2014-10-13 English
PHARMING TO SOUND THE GONG TO OPEN AMSTERDAM MARKET TO MARK A SUMMER OF SIGNIFICANT STRATEGIC PROGRESS FOR PHARMING
Regulatory Filings Classification · 95% confidence The document is a press release dated September 2, 2014, announcing significant strategic progress made over the summer, including FDA approval of RUCONEST®, initiation of a Phase II clinical study, and an asset acquisition. It details key business and regulatory milestones but is not a formal periodic report (like 10-K or IR), a transcript (CT), or a formal dividend/share change notice. It functions as an update on business developments and regulatory achievements, which aligns best with a general announcement or an Investor Presentation/Information release, although it lacks the typical slide format of an IP. Given the content focuses heavily on regulatory approvals (FDA) and commercial progress, it is a high-level business update. Since it is not a formal financial report, nor a specific transaction notice, and it is not announcing the release of another document (RPA), the most fitting category for a press release detailing major business and regulatory achievements is often the general 'Regulatory Filings' (RNS) if no better fit exists, or potentially 'Investor Presentation' (IP) if it were more strategic/forward-looking. However, this reads like a standard corporate news release highlighting recent achievements. Given the options, and the lack of a specific 'Press Release' category, 'RNS' serves as the best general regulatory announcement fallback, although 'ER' (Earnings Release) is sometimes used loosely for major updates, this is not explicitly tied to a quarterly earnings period announcement. I will classify this as a general Regulatory Filing (RNS) as it is a broad announcement of corporate events.
2014-09-02 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.